Self Administered Injectable Drugs to Reach $100 Billion Globally by the End of the Decade

Growth will be impacted by Generics and New Oral APIs, according To Greystone Research Associates

(Amherst, NH) – Self administered injectable drugs, a class that includes prescribed therapeutics for anti-inflammatories, antivirals, anemia, hormone replacement, fertility, osteoporosis, anticoagulants, and drugs for controlling diabetes, have grown at a CAGR of 7.7% over the past six years, as enhancements in self-injection devices have converged with improved drugs that cannot be administered orally. Based on developments in the past nine months were are now forecasting self administered injectables to reach $100 billion on an ex-manufacturer revenue basis in 2020.

In the self administered injectables market sector, anti-inflammatory drugs, including drugs to treat autoimmune diseases, are the largest single segment representing 36% (revenue basis) of the global market in 2013. We are projecting that this segment will grow to comprise 42% of all self administered injectables by 2020.

Insulins and insulin analogs represent the second largest therapeutic area, at 21.6% (25.3% by 2020). Injectable drugs indicated for glycemic control in Type 2 diabetics represent another important self administered injectables segment. Led by Novo Nordisk’s Victoza, these GLP-1 analogs grew at a CAGR of 26 percent from 2007 through 2013. Self-injectables for Type 2 diabetes currently represent 3.1 percent of the self administered injectables sector. We are projecting an increase in market share to 6.9 percent by the end of the decade.

Beyond the top two self administration segments, specialty injectables revenue growth will be decidedly mixed, as several therapeutic segments experience price pressure from generics, and volume pressure from new oral formulations. A harbinger of things to come can be seen in injectable anticoagulants. Total branded anticoagulant revenue has dropped by half since the introduction of generic versions of Sanofi’s Lovenox brand of low molecular weight heparin.

Injectable interferons for treating Hepatitis C (HCV) will see revenue drop as they compete with Gilead’s Sovaldi, an oral drug that was approved by the FDA at the end of 2013 and is already a billion dollar product. Roche/Genentech’s PEGASYS pegylated interferon has already seen revenue decreases of 11% in the first half of 2014, after excluding the impact of currency fluctuations.

Injectable hematopoietics, a drug class that includes erythropoietins and colony stimulating factors, is starting to encounter the first competition from biosimilars outside of North America. Biosimilar competitors in this therapeutic segment include Sandoz and Hospira.

Detailed analysis of specialty injectable drugs, therapeutic sectors, and participants is included in a new and comprehensive report. Self Administered Injectables to 2020, researched and written by Greystone Research Associates, analyzes self administered injectable drugs across eleven major therapeutic drug segments, assesses market risks and opportunities, examines regulatory and market factors and profiles market participants.

More information is available at
http://www.greystoneassociates.org/Injectable_Delivery.htm

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.